𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Vitiligo in the Nigerian African: a study of 351 patients in Benin City, Nigeria

✍ Scribed by Abel N. Onunu; Emmanuel P. Kubeyinje


Book ID
104464003
Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
72 KB
Volume
42
Category
Article
ISSN
0011-9059

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Background There is a paucity of reports on vitiligo in sub‐Saharan Africa.

Aim To define the clinical and epidemiologic pattern of vitiligo in the Nigerian African.

Methods We examined all new cases of vitiligo seen in the Dermatology Unit of the University of Benin Teaching Hospital (UBTH) over a 14‐year period: January 1985 to December 1998.

Results Three hundred and fifty‐one patients with vitiligo, representing 3.2% of new dermatologic cases, were enrolled. The study group was made up of 153 males and 198 females, giving a sex ratio of 1Β :Β 1.3. The peak incidence of vitiligo was in the second and third decades of life, and the most common form of presentation was the localized focal type (77%), followed by the segmental type (12.5%) and the generalized form (10.5%). Common sites affected were the limbs (32%), trunk (23.8%), face (18.2%), head and neck (9.1%), and the mucous membranes (7.4%). There was a positive family history of vitiligo in 18% of subjects and 3.4% had systemic diseases, such as diabetes mellitus (1.7%), anemia (0.8%), hyperthyroidism (0.6%), and leukemia (0.3%).

Conclusions Vitiligo on darkly pigmented skin is often a very striking disease. Our findings show that the pattern of vitiligo is similar to that reported from other parts of the world. The high level of social stigmatization is due to confusion with leprosy.


πŸ“œ SIMILAR VOLUMES


Barriers to the participation of African
✍ Anjali S. Advani; Benjamin Atkeson; Carrie L. Brown; Bercedis L. Peterson; Laura πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 94 KB πŸ‘ 2 views

## Background: African-american patients have been under-represented in oncology clinical trials. better understanding barriers to african-american participation may help increase the accrual of african-american patients onto clinical trials. ## Methods: Two hundred eighteen patients with maligna